Organization | Goethe University

Goethe University Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4

Organization Overview

First Clinical Trial

2002

NCT00199082

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Now

Alternative names

Gerd Geisslinger | Nicola Goekbuget

Active Ingredients

Drugs in Phase 4 Trials (11)

cyclophosphamide (cytoxan) (1 trial)

cytarabine (cytosar-u) (1 trial)

doxorubicin (Doxil) (1 trial)

etoposide (vepesid) (1 trial)

ifosfamide (ifex) (1 trial)

naltrexone (revia) (1 trial)

prednisone (meticorten) (1 trial)

rituximab (rituxan) (1 trial)

sargramostim (leukine) (1 trial)

vincristine (oncovin) (1 trial)

Drugs in Phase 2 Trials (1)

inotuzumab ozogamicin (besponsa) (1 trial)

Drugs in Phase 1 Trials (1)

flurbiprofen (ansaid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Burkitt Lymphoma (Phase 4)

Leukemia (Phase 4)

Leukemia, Lymphoid (Phase 2)

Lymphoma (Phase 4)

Lymphoma, Large-Cell, Anaplastic (Phase 4)

Lymphoma, Non-Hodgkin (Phase 4)

Mediastinal Neoplasms (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 3
# of Trial APIs: 13